Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation

Aim. To study clinical prognostic value of residual platelet activity in patients with acute coronary syndrome without ST segment elevation. Material and methods. The study included 120 patients with acute coronary syndrome without ST segment elevation (NSTE ACS) with coronary artery stenting. Testing of residual reactivity of platelets in the subjects was carried out after loading doses of  aspirin and P2Y12-inhibitors.Patients were divided into two groups comparable in gender and age: with low residual reactivity of platelets (LRR), n=90 and with high residual reactivity of platelets (HRR), n=30. Between the groups a comparative assessment of clinical-laboratory and instrumental indicators, development of a combined end point (ischemic events) and bleeding during follow-up (16 ± 6 months). Results. The group with HRR was initially heavier: patients with angina pectoris of functional class III, atrial fibrillation, myocardial infarction, was a higher risk on the GRACE (202,6±11 vs. 148,6±7, р=0,03),increased levels of Troponin T (70,0 vs. 45,5%, р=0,02), acute occlusion in the coronary arteries (66,6 vs. 42,4%, р=0,02).The combined endpoint was more often reported in patients with HRR (40 vs. 20,7%, р=0,04). Patients with ADP-aggregation of platelets in the range 0–1 Om had a greater risk of developing hemorrhagic events (17,1 vs. 2,1%, RR 8,05 CI: 1,1–59,9, р=0,01). Conclusion. In patients with NSTE ACSHRR after loading doses of aspirin and P2Y12-inhibitor was associated with the development of repeated atherothrombotic events. Very low LRR was associated with the development of bleeding.

acute coronary syndrome without ST segment elevation, functional activity of platelets, transcutaneous coronary intervention, double antiplatelet therapy

1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541–619. DOI: 10.1093/eurheartj/ehu278

2. Gratsiansky N.A. Antiplatelet therapy for coronary heart disease. Some challenges and achievements. Atherothrombosis. 2010;1:2–86. [Russian: Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз. 2010;1:2-86]

3. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis. 2011;106(08):191–202. DOI: 10.1160/TH11-01-0040

4. Breet NJ. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA. 2010;303(8):754–62. DOI: 10.1001/jama.2010.181

5. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated with Ischemia and Bleeding. Journal of the American College of Cardiology. 2013;62(24):2261–73. DOI: 10.1016/j.jacc.2013.07.101

6. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal. 2014;35(4):209–15. DOI: 10.1093/eurheartj/eht375

7. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. The Lancet. 2013;382(9892):614–23. DOI: 10.1016/S0140-6736(13)61170-8

8. Alekyan B.G., Abugov S.A., Andreev D.A., Buryachkovskaya L.I., Vavilova T.V., Vershinina M.G. et al. The role of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology. 2014;10(6):679–87. [Russian: Алекян Б.Г., Абугов С.А., Андреев Д.А., Бурячковская Л.И., Вавилова Т.В., Вершинина М.Г. и др. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Рациональная Фармакотерапия в Кардиологии. 2014;10(6):679-87]

9. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320

10. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47. DOI: 10.1161/CIRCULATIONAHA.110.009449

11. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet. 2010;375(9711):283–93. DOI: 10.1016/S0140-6736(09)62191-7

12. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study. Circulation. 2010;121(10):1188–99. DOI: 10.1161/CIRCULATIONAHA.109.919456

13. Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K et al. ReducedFunction CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI: A Meta-analysis. JAMA. 2010;304(16):1821–30. DOI: 10.1001/jama.2010.1543

14. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S et al. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function. Journal of the American College of Cardiology. 2013;61(8):872–9. DOI: 10.1016/j.jacc.2012.11.040

15. Yusuf S, Fox KA, Tognoni G, Mehta SR. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine. 2001;345(7):494–502. DOI: 10.1056/NEJMoa010746

16. Udell JA, Bonaca MP, Collet J-P, Lincoff AM, Kereiakes DJ, Costa F et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal. 2015;37(4):390–9. DOI: 10.1093/eurheartj/ehv443

17. Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T et al. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 2014;35(6):353–64. DOI: 10.1093/eurheartj/eht407

18. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS et al. A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine. 2011;364(3):226–35. DOI: 10.1056/NEJMoa1002358

19. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I et al. Clopidogrel Resistance Is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. Circulation. 2004;109(25):3171–5. DOI: 10.1161/01.CIR.0000130846.46168.03

20. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal. 2007;154(2):221–31. DOI: 10.1016/j.ahj.2007.04.014